JP2025542384A - 少なくともｅｇｆｒに結合する抗体及び免疫チェックポイント阻害剤を使用したがんの併用療法 - Google Patents

少なくともｅｇｆｒに結合する抗体及び免疫チェックポイント阻害剤を使用したがんの併用療法

Info

Publication number
JP2025542384A
JP2025542384A JP2025536839A JP2025536839A JP2025542384A JP 2025542384 A JP2025542384 A JP 2025542384A JP 2025536839 A JP2025536839 A JP 2025536839A JP 2025536839 A JP2025536839 A JP 2025536839A JP 2025542384 A JP2025542384 A JP 2025542384A
Authority
JP
Japan
Prior art keywords
antibody
derivative
cancer
egfr
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025536839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025542384A5 (cg-RX-API-DMAC10.html
Inventor
アーネスト・アイザック・ワッサーマン
エドゥアルド・ホセ・ペネラ
Original Assignee
メルス ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2025542384A publication Critical patent/JP2025542384A/ja
Publication of JP2025542384A5 publication Critical patent/JP2025542384A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2025536839A 2022-12-23 2023-12-22 少なくともｅｇｆｒに結合する抗体及び免疫チェックポイント阻害剤を使用したがんの併用療法 Pending JP2025542384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2033821 2022-12-23
NL2033821 2022-12-23
PCT/NL2023/050684 WO2024136658A1 (en) 2022-12-23 2023-12-22 Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor

Publications (2)

Publication Number Publication Date
JP2025542384A true JP2025542384A (ja) 2025-12-25
JP2025542384A5 JP2025542384A5 (cg-RX-API-DMAC10.html) 2026-04-21

Family

ID=85172568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025536839A Pending JP2025542384A (ja) 2022-12-23 2023-12-22 少なくともｅｇｆｒに結合する抗体及び免疫チェックポイント阻害剤を使用したがんの併用療法

Country Status (10)

Country Link
US (1) US20260217836A1 (cg-RX-API-DMAC10.html)
EP (1) EP4637817A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025542384A (cg-RX-API-DMAC10.html)
KR (1) KR20250124833A (cg-RX-API-DMAC10.html)
CN (2) CN120583961A (cg-RX-API-DMAC10.html)
AU (1) AU2023408531A1 (cg-RX-API-DMAC10.html)
IL (1) IL321614A (cg-RX-API-DMAC10.html)
MX (1) MX2025007322A (cg-RX-API-DMAC10.html)
TW (1) TW202432605A (cg-RX-API-DMAC10.html)
WO (1) WO2024136658A1 (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500405A (ja) * 2015-10-23 2019-01-10 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TWI717401B (zh) 2015-10-20 2021-02-01 南韓商東友精細化工有限公司 整合有偏光板之窗口基板、及製備該窗口基板之方法
IL303633A (en) * 2020-12-15 2023-08-01 Merus Nv Cancer treatment with an antibody that binds LGR5 and EGFR
CN120504741A (zh) * 2021-10-06 2025-08-19 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500405A (ja) * 2015-10-23 2019-01-10 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HERPERS, B. ET AL., NAT CANCER, vol. 3, JPN6026024995, April 2022 (2022-04-01), pages 418 - 436, ISSN: 0005892839 *
HOLLEBECQUE, A. ET AL.: "Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in", AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS (2021), JPN6026024996, October 2021 (2021-10-01), ISSN: 0005892838 *

Also Published As

Publication number Publication date
EP4637817A1 (en) 2025-10-29
KR20250124833A (ko) 2025-08-20
TW202432605A (zh) 2024-08-16
CN122031678A (zh) 2026-05-15
AU2023408531A1 (en) 2025-07-17
US20260217836A1 (en) 2026-07-30
WO2024136658A1 (en) 2024-06-27
CN120583961A (zh) 2025-09-02
MX2025007322A (es) 2025-07-01
IL321614A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7450592B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP7573062B2 (ja) がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
JP7568698B2 (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2023520771A (ja) 多発性骨髄腫を処置する方法
TW202404644A (zh) 用於治療腫瘤抗原表現性癌症之組合療法
JP2026083251A (ja) 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
CA3202006A1 (en) Treatment of cancers with an antibody that binds lgr5 and egfr
AU2023418141A1 (en) Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
KR20250124833A (ko) 적어도 egfr에 결합하는 항체 및 면역 관문 저해제를 사용한 암의 병용 치료
HK40091842A (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
HK40109234A (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250916

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623